Advertisement
"As the clinical benefits of CyberKnife radiosurgery have evolved beyondbrain and spine tumors into extracranial applications, such as lung andprostate, we have seen the number of radiosurgery cases increase significantlyover the past few years. With the purchase of a second CyberKnife System, wewill be able to meet this high demand for precise, accurate radiosurgicaltreatment throughout the body while still maintaining short waiting times forour patients with intracranial and spine tumors, and AVMs," said ProfessorFederico Colombo, Director of the Neurosurgical Department at VicenzaHospital. "The CyberKnife's ability to deliver accurate radiosurgicaltreatments quickly and easily anywhere in the body was a decisive factor inchoosing our second system."
Advertisement
In 2003, Vicenza Hospital was the first facility in Europe to install aCyberKnife System, which has been used primarily to treat arteriovenousmalformations (AVM) and benign tumors in the brain such as neuromas andmeningiomas. To date, the hospital, which is located in the Venetian regionof Italy, has treated almost 1,800 patients with the CyberKnife System.
"As CyberKnife radiosurgery has evolved to address tumors anywhere in thebody, demand for the treatment often becomes more than a single CyberKnifeSystem can accommodate," said Euan S. Thomson, Ph.D., president and CEO ofAccuray. "Vicenza Hospital's expansion echoes a trend we have been witnessingin the United States, in which facilities require multiple CyberKnife Systemsto manage growing patient demand and expanded treatment offerings, includingtumors in the lungs, prostate, pancreas, kidney or liver."
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only roboticradiosurgery system designed to treat tumors anywhere in the bodynon-invasively. Using continual image guidance technology and computercontrolled robotic mobility, the CyberKnife System automatically tracks,detects and corrects for tumor and patient movement in real-time throughoutthe treatment. This enables the CyberKnife System to deliver high-doseradiation with pinpoint precision, which minimizes damage to surroundinghealthy tissue and eliminates the need for invasive head or body stabilizationframes.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is aglobal leader in the field of radiosurgery dedicated to providing an improvedquality of life and a non-surgical treatment option for those diagnosed withcancer. Accuray develops and markets the CyberKnife Robotic RadiosurgerySystem, which extends the benefits of radiosurgery to include extracranialtumors, including those in the spine, lung, prostate, liver and pancreas. Todate, the CyberKnife System has been used to treat more than 50,000 patientsworldwide and currently more than 145 systems have been installed in leadinghospitals in the Americas, Europe and Asia. For more information, pleasevisit http://www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involverisks and uncertainties, including uncertainties associated with the medicaldevice industry. Except for the historical information contained herein, thematters set forth in this press release, including statements relating toclinical studies, regulatory review and approval, and commercialization ofproducts are forward-looking statements within the meaning of the "safeharbor" provisions of the Private Securities Litigation Reform Act of 1995.Forward-looking statements speak only as of the date the statements are madeand are based on information available at the time those statements are madeand/or management's good faith belief as of that time with respect to futureevents. You should not put undue reliance on any forward-looking statements.Important factors that could cause actual performance and results to differmaterially from the forward-looking statements we make include: marketacceptance of products; competing products, the combination of our productswith complementary technology; and other risks detailed from time to timeunder the heading "Risk Factors" in our report on Form 10-K for the year endedJune 30, 2008 as updated from time to time by our quarterly reports on Form10-Q and our other filings with the Securities and Exchange Commission. TheCompany's actual results of operations may differ significantly from thosecontemplated by such forward-looking statements as a result of these and otherfactors. We assume no obligation to update forward-looking statements toreflect actual performance or results, changes in assumptions or changes inother factors affecting forward-looking information, except to the extentrequired by applicable securities laws.
SOURCE Accuray Incorporated
